FDA Declines to Expand Approval of Pfizer Arthritis Drug Xeljanz

U.S. health regulators declined to approve Pfizer Inc's oral rheumatoid arthritis drug Xeljanz (tofacitinib) to treat moderate to severe cases of plaque psoriasis, the drugmaker said on Wednesday.